B. Lespérance

发表

Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO).

J. Ouellet, G. Boily, N. Letarte, 2013, Gynecologic oncology.

Developing and maintaining the resilience of interdisciplinary cancer care teams: an interventional study

M. Lavoie-Tremblay, Kathleen Bentein, A. Marchand, 2020, BMC Health Services Research.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Mads Thomassen, Nina Ditsch, Vijai Joseph, 2012, Breast Cancer Research.

Inhibition of Streptokinase‐Induced, Antibody‐Mediated Platelet Aggregation with Tirofiban After Exposure to Streptokinase or Streptococcal Infection

J. Diodati, D. Palisaitis, C. Pharand, 2004, Pharmacotherapy.

Platelet activity and antibody titers after exposure to streptokinase or streptococcal infection.

J. Diodati, D. Palisaitis, C. Pharand, 2003, Thrombosis research.

Partnering in Oncogenetic Research – The INHERIT BRCAs Experience: Opportunities and Challenges

B. Knoppers, B. Godard, D. Easton, 2005, Familial Cancer.

nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

H. Kennecke, S. Dowden, R. El-Maraghi, 2016, Advances in Therapy.

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

C. Sotiriou, C. Desmedt, D. Larsimont, 2004, Molecular cancer therapeutics.

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012, Breast Cancer Research.

Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer

B. Knoppers, B. Godard, D. Easton, 2006, Journal of Medical Genetics.

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine

G. Batist, D. Bachvarov, B. Chabot, 2013, Modern Pathology.

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families

D. Labuda, S. Tavtigian, J. Simard, 2006, BMC Cancer.

No Evidence of BRCA 1 / 2 Genomic Rearrangements in High-Risk French-Canadian Breast / Ovarian Cancer Families

M. Dumont, J. Simard, D. Goldgar, 2009 .

No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families.

M. Dumont, J. Simard, D. Goldgar, 2006, Genetic testing.

A new alternative splice variant of BRCA1 containing an additional in-frame exon.

M. Dumont, J. Simard, Y. Labrie, 2005, Biochimica et biophysica acta.

Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer

C. Greenwood, G. Batist, S. Tejpar, 2021, Clinical and translational medicine.

Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families

Frédéric Guénard, Charles Joly Beauparlant, Francine Durocher, 2007, Familial Cancer.

HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

D. Larsimont, M. Piccart, K. Friedrichs, 2004, Breast Cancer Research and Treatment.

Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high‐risk non BRCA1/2 French Canadian breast and ovarian cancer families

Y. Labrie, J. Chiquette, R. Laframboise, 2008, International journal of cancer.

Relative Sensitivity of Different Tests in the Detection of Low Titer Lupus Anticoagulants

C. Infante-Rivard, G. Rivard, J. Rauch, 1988, Thrombosis and Haemostasis.

A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.

R. Langley, R. Meyer, S. Caplan, 1998, Leukemia & lymphoma.

nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

H. Kennecke, S. Dowden, R. El-Maraghi, 2016, Advances in Therapy.

q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, B. Bonanni, 2012 .

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families

S. Tavtigian, J. Simard, O. Sinilnikova, 2006, BMC Cancer.

Common variants at 12 p 11 , 12 q 24 , 9 p 21 , 9 q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers

V. Pankratz, F. Couch, David Evans, 2017 .